Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.